Multiple meyloma
Conditions
Interventions
Sponsors
The Department of Hematology, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years, no gender limitations; 2.Relapsed or newly diagnosed multiple myeloma who have recieved induction regimens and prepared for stem cell mobilization in autologous stem cell transplantation; 3.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2; 4.Life expectancy of more than 3 months; 5.Total bilirubin <= 2.0mg/dL, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 times the upper limit of normal; 6.Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with known sensitivity to melphalan or bendamustine and the accessories ; 2.The patient also has other tumors or has a history of tumors; 3.Active hepatitis B virus infect, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive; 4Patients had uncontrolled or severe cardiovascular disease, including myocardial infarction within 6 months prior to enrollment, NYHA defined class III to IV heart failure, uncontrolled angina, congestive heart failure, clinically significant pericardial disease, or cardiac amyloidosis (NT-Pro-BNP>=1800pg/mL); 5.The patient also had severe infectious disease; 6.If the patient has a serious physical or mental illness that may interfere with participation in the clinical study, as determined by protocol or investigator; Substance abuse, medical, psychological, or social conditions that may interfere with the subjects' participation in the study or evaluation of the study results; 7.Patients receiving other experimental drugs; 8.Female patients who are lactating or pregnant; 9.Other patients not appropriate for the trial in the judgement of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission and above remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival rate;Overall survival rate;Minimal residual disaese negative rate;Safety; | — |
Countries
China
Contacts
Public ContactNiu Ting
West China Hospital, Sichuan University
Outcome results
None listed